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 Abstract 
 Among different prognostic factors in Chronic Lymphocytic Leukemia 
(CLL), we previously demonstrated that lipoprotein lipase (LPL) is 
associated with an unmutated immunoglobulin profi le and clinical 
poor outcome. Despite the usefulness of LPL for CLL prognosis, its 
functional role and the molecular mechanism regulating its 
expression are still open questions. Interaction of CLL B-cells with 
the tissue microenvironment favors disease progression by promot-
ing malignant B-cell growth. Since tissue methylation can be altered 
by environmental factors, we investigated the methylation status 
of LPL gene and the possibility that overexpression could be 
associated with microenvironment signals. Our results show that a 
demethylated state of the LPL gene is responsible for its anomalous 
expression in unmutated CLL cases and that this expression is 
dependent on microenvironment signals. Overall, this work proposes 
that an epigenetic mechanism, triggered by the microenvironment, 
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Abstract 
Among different prognostic factors in Chronic Lymphocytic Leukemia (CLL), we 
previously demonstrated that lipoprotein lipase (LPL) is associated with an 
unmutated immunoglobulin profile and clinical poor outcome. Despite the 
usefulness of LPL for CLL prognosis, its functional role and the molecular 
mechanism regulating its expression are still open questions. Interaction of CLL 
B-cells with the tissue microenvironment favors disease progression by 
promoting malignant B-cell growth. Since tissue methylation can be altered by 
environmental factors, we investigated the methylation status of LPL gene and 
the possibility that overexpression could be associated with microenvironment 
signals. Our results show that a demethylated state of the LPL gene is 
responsible for its anomalous expression in unmutated CLL cases and that this 
expression is dependent on microenvironment signals. Overall, this work 
proposes that an epigenetic mechanism, triggered by the microenvironment, 
regulates LPL expression in CLL disease. 





































































Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, with survival 
ranging from months to decades. The development of the Rai and Binet staging 
systems has allowed the division of patients with CLL into three prognostic 
groups: good, intermediate and poor prognosis. The two staging systems have 
improved the identification of patients who need immediate treatment. However, 
neither the Rai nor the Binet staging system can predict which patients among 
the good prognosis group will have progressive disease [1]. Major progress has 
been made to identify molecular and cellular markers that predict disease 
progression in CLL patients. Among these markers, cytogenetic abnormalities 
including 11q or 17p deletions in the leukemic B cells, or the presence of an 
unmutated (Um) status of the immunoglobulin heavy chain genes (IGHV) are 
the better predictors of rapid progression and shorter survival [1]. 
Gene-expression profiling (GEP) has introduced a new dimension into 
our understanding of CLL biology and clinical behavior. Results from GEP in 
CLL led us to propose that aberrant over-expression of the lipoprotein lipase 
(LPL) gene is a surrogate marker of the mutational status of IGHV [2]. This 
observation was extensively confirmed by other groups [3-7]. Thus, LPL mRNA 
over-expression is currently demonstrated to be associated with Um status and 
clinical poor outcome and also it appears to be the most powerful prognostic 
tool among RNA-based markers in CLL[8]. 
Previous work suggests a role for LPL expression in CLL disease, not 
only in gene expression changes but also in functional pathways related to fatty 
acid degradation and signaling, which may influence CLL cell behavior [9]. 
Despite these studies and though the prognostic value of LPL gene is well 
established, the functional consequences of LPL over-expression in CLL 
pathogenesis as well as the molecular mechanism regulating its expression 
remain elusive. 
Aberrant DNA methylation has been shown to play a strong role in 
tumorigenesis, where genome-wide hypomethylation and regional 
hypermethylation of tumor suppressor gene promoters are characteristic 
hallmarks of many cancers. Tissue specific patterns of methylated cytosine 
residues can be altered by environmental factors, and are often abnormal in 
tumor disorders [10]. 
The main goal of this investigation was to obtain deep insight into the 
molecular mechanisms responsible for the high expression of LPL in Um CLL B-
cells. In this line, we investigated the methylation status of the LPL gene 
promoter region, as well as the possibility that its expression could be related to 
specific signals delivered by the microenvironment. 
Our results suggest that demethylated status of LPL gene is responsible 
for the anomalous expression of this prognostic marker in Um CLL and that this 
epigenetic mechanism, can be induced in the leukemic clone by 
microenvironment signals. 




































































Patient samples and clinical data. 
Peripheral blood mononuclear cells (PBMC) were obtained from 26 
patients with CLL. Samples were characterized at a molecular level through 
CD38, LPL expression, and IGHV status as well as fluorescence in-situ 
hybridization (FISH) analysis. Supplementary Table 1. All patients were followed 
at the Hospital Maciel, Montevideo and provided an informed consent in 
accordance with the ethical regulations from Uruguay and the Helsinki 
Declaration. 
RNA Extraction and analysis of LPL transcripts by PCR. 
Genomic DNA, RNA extraction, cDNA synthesis, reverse transcription–
polymerase chain reaction (RT-PCR) and quantitative PCR (Q-PCR) for LPL 
amplification were performed as described [2]. 
Methylation Analysis and 5-Aza-2´-deoxycytidine treatment. 
CpG island in the 5'-region of LPL gene was identified by 
EMBOSS/CpGPlot/CpGReport/Isochore software. Five hundred ng of genomic 
DNA was treated with sodium bisulphite and amplified using Bisulphite-
sequencing primers. Five clones of each CLL patients were cloned and 
sequenced to evaluate the methylation status of CpG island. In order to confirm 
the specificity of methylation changes in the LPL methylation status Daudi cell 
line was cultured over 3 and 5 days in supplemented RPMI media containing 
10µM 5-Aza-2´-deoxycytidine (5-Aza-dC) (Sigma Aldrich, USA). Medium was 
changed every 24 hours and bisulphite analysis was carried out as describe 
above. 
CLL B-cells stimulation with different microenvironment signals. 
Stimulation of PBMCs on negative LPL expression patients with 
autologous T-cells or with recombinant CD40L and IL-4 were performed as 
described in [11] and [12], respectively. In turn, B-Cell receptor (BCR) 
stimulation was achieved by anti-IgM (Jackson ImmunoResearch, USA) 
immobilized to culture plates at 15µg/ml and the cells collected after 4 days. 
Flow cytometry analysis. 
1x106 PBMCs were incubated for 45 minutes at 4°C with anti-CD19-
PerCP, anti-CD25-PE, anti-CD80-PE, and anti-CD86-FITC, (BD Biosciences, 
CA, USA). The cells were then washed and analyzed. Negative isotype controls 
were performed with irrelevant antibody in the same conditions. Results were 
analyzed by Summit v4.3 software (Dako Inc., CA, USA). 
Epifluorescence microscopy. 
For intracellular detection of LPL, indirect immunofluorescence technique 
was performed using mAb anti-LPL, 5D2 antibody (kindly provided by Dr. J. 
Brunzell, University of Washington). PBMC from CLL patients were isolated by 
B-Cell Isolation Kit for B-CLL (http://www.miltenyibiotec.com), washed with PBS 
and 5U/ml heparin (Sigma Aldrich, USA), fixed with 3.7% paraformaldehyde and 
permeabilized with 0.1% Triton X-100 in PBS. Nonspecific binding was blocked 
with 5% FBS in PBS, incubated with anti-LPL antibody in overnight at 4ºC, and 




































































Carlsbad, CA, USA) for 1hr. Nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI). After washes, preparations were visualized (100X) and 
photographed in Olympus inverted microscope CKX31. 
Statistical analyses. 
Expression of LPL mRNA, CD25, CD80 and CD86 as activation control 
proteins and methylation percentage of R1-LPL region were compared between 
control samples and different activations subsets using either paired Wilcoxon 
Signed Rank Test or two tailed unpaired Student's t-test. Variables with P 
values of less than 0.05 were considered to be significant. The Spearman rank 
correlation coefficient was calculated to determine the strength of association 
between LPL expression and methylation percentage. P values ≤ 0.01 are 
considered significant. All analyses were done using GraphPad Prism, version 
5.0 (GraphPad Software, San Diego, CA). 
Results 
The first exon/intron within the core promoter of LPL gene is differentially 
methylated in Mutated and Unmutated CLL patients. 
In order to address whether LPL gene can be regulated epigenetically 
through CpG methylation, we analyzed the CpG sites in the LPL gene. This 
analysis revealed CpG-rich sequences encompassing a classical CpG-island of 
1163 bp with 112 CpG dinucleotides. This region is located within the first exon 
and the first intron of the LPL gene. To better characterize this CpG island we 
focused on methylation status of CpG dinucleotides in two different regions (R1 
= 248bp, from +87 bp to +335bp and R2 = 261bp, from + 446bp to +707bp) 
(Figure 1A-C). Methylation of the first exon is critical for transcriptional silencing 
[10]. Accordingly with this, our initial results comparing methylation changes 
between these two regions in 6 CLL samples showed that main differences 
appeared to be restricted to R1 (exon 1, CpG dinucleotides number 1-18) and to 
R2 (first region of intron 1, CpG dinucleotides number 19-23) (Figure 1C). 
Following this, 26 CLL patients (14 Um expressing LPL and 12 Mut negative for 
LPL mRNA, Supplementary table 1) were analyzed by bisulphite DNA 
conversion and sequencing methodology focusing on the R1 of LPL-CpG island 
(Figure 1C). We found that Mut CLL cases which did not express, or expressed 
minimal levels of LPL mRNA had a methylated R1 profile. In contrast, Um CLL 
cases expressing higher levels of LPL mRNA, displayed a demethylated profile 
of this region (Figure 1D). Overall, these results suggest that differential 
methylation status is responsible for LPL gene expression in Mut and Um CLL 
patients. 
LPL expression correlates with the methylated status of CpG island and 
depends on microenvironment signals. 
To confirm previous results linking LPL expression with a demethylation 
status, we studied the LPL mRNA expression of these 26 CLL patients by RQ-
PCR. A significant correlation (p < 0.0001) between LPL expression and a 
demethylated status in Um CLL patients and absence of LPL expression and a 




































































the epigenetic mechanism of LPL expression we exposed the LPL-negative 
Daudi cells to 5-Aza-dC, a DNA methyltransferase inhibitor. Result showed that 
exposure to this drug triggered mRNA LPL expression at significant levels 
compared with untreated cells (3 and 5 days, p < 0.01), and was also able to 
induce a demethylation of R1-LPL region, Figure 2B. These data confirm that 
demethylation in Exon 1/Intron 1 of LPL gene is correlated with the expression 
of this prognostic marker in leukemic CLL B-cells. Additionally, we asked 
whether LPL anomalous expression in leukemic B-cells could be related to the 
microenvironment signals. To obtain deep insight in this hypothesis, PBMC from 
three negative LPL samples were incubated with or without autologous T-cells, 
activated through TCR cross-linking. After 4 days, CD19/CD5 positive cells were 
purified and mRNA LPL expression and the methylation status of R1-LPL region 
were evaluated. As depicted in figure 2C, we found that following autologous T 
cell activation the leukemic clone expressed LPL and altered the methylation 
status of R1 LPL-region into a mostly unmethylated pattern. To confirm this 
result we also stimulated another 6 LPL negative patients through CD40 and IL-
4 receptors or through the B cell receptor (BCR). Both activation protocols were 
able to induce LPL mRNA and protein expression and it was associated with 
DNA demethylation of R1-LPL region. One representative LPL negative CLL 
patient with or without stimulations is shown (Figure 2D). Overall, these results 
suggest that LPL expression in CLL is related with proliferative 
microenvironment signals that appear to induce a demethylation process in the 
leukemic clone. 
DISCUSSION 
Although it has traditionally been assumed that CLL is the consequence 
of long lived tumor cell accumulation, evidence indicates that disease evolution 
results from the balance between proliferating cells in specialized tissue 
microenvironment and circulating cells resisting apoptosis [13]. This equilibrium 
is finely tuned by a set of surface molecules expressed by CLL B cells and 
modulated in response to environment signals [14]. 
Since there is no expression of LPL in normal B cells, the presence of 
high levels of LPL in Um CLL B-cells is a very interesting issue. This anomalous 
expression constitutes not only a suitable prognostic marker for the disease but 
could also be helpful to understand the heterogeneous proliferative behavior of 
CLL-B cells. 
At physiological level, the largest expression of LPL gene has been 
reported in adipose tissue, skeletal muscle, heart tissue, dendritic cells and 
CD33 myeloid cells [9]. LPL is a protein located on the luminal side of the wall 
vessels, where it is anchored to heparan sulfate proteoglycans and contains 
binding sites for heparan sulfate chains and apoproteins [15]. Furthermore, LPL 
has a bridging function in the formation of a trimolecular complex including a 
lipoprotein particle, LPL and heparan sulfate proteoglycans from different cells 
[15]. This is an interesting characteristic of LPL because, independently of its 
catalytic function, LPL expression in Um CLL patients may be associated with 




































































the case, LPL might also act as a crosstalk factor facilitating specific interactions 
with accessory cells in the tissue microenvironment. 
The results present here connect tumor cell proliferation with epigenetic 
changes on the CpG island of LPL DNA suggesting that LPL expression in CLL 
is related with microenvironment signals that appear to induce a demethylation 
process in the leukemic clone. This data is supported by the fact that anomalous 
LPL expression is a hallmark of Um CLL patients. 
In conclusion, this work shows that an epigenetic mechanism, triggered 
by the microenvironment, is responsible for the anomalous LPL expression in 
Um CLL patients. 
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CpG island analysis of LPL gene in CLL patients. (A) Localization of the 
CpG island of LPL gene. CpG island was defined as the region containing over 
50% of CpG dinucleotides by EMBOSS/CpGPlot/CpGReport/Isochore software. 
(B) Schematic representation of exon 1 and intron 1 within CpG island of LPL 
gene. The position of exon1, intron1, the transcription start site (TSS) and the 
PCR primers for R1 and R2 are depicted as a, b, c and d. (C) R1 and R2 profile 
methylation differences. Methylation analysis of R1 and R2-LPL region was 
performed in 6 CLL cases (3 Mut and 3 Um) in order to visualize the main 
changes in the methylation status of both subsets. Shadow squares highlight 
the fact that the major differences concerning the methylation profile are placed 
in R1 and not in R2. Each row represents one bacterial clone in which black and 
white circles represent methylated and unmethylated CpG dinucleotides, 
respectively. (D) Differential expression of LPL gene and methylation status in 
Mut and Um CLL patients. Results from five Mut (1–5) and five Um (14–18) 
representative CLL patients, Daudi cell line and adipose tissue samples as 
negative and positive controls, respectively, are depicted. LPL mRNA 
expression evaluated by RT-PCR is shown in agarose gel stained with ethidium 
bromide. GAPDH was amplified in all cases as internal control. Methylation 
status evaluated by bisulphate sequencing of R1-LPL region is shown as 
lollipop diagrams. Each row represents one bacterial clone in which black and 










































































































































LPL expression and methylation changes analysis after incubation with 
demethylated agents or microenvironment signals. (A) Correlation between 
LPL mRNA expression of 14 Mut and 12 Um CLL patients evaluated by 
quantitative reverse transcription PCR and methylation percentage in R1-LPL 
region. Statistical analysis indicating a significant correlation by Spearman’s 
rank (P-values ≤ 0.001) is shown. In this case LPL expression was correlated to 
methylation status (P < 0.00015; Spearman’s rank coefficient P = 0.72) in 26 
CLL samples. (B) Activation of LPL expression and DNA demethylation after 5-
Aza-dC treatment. LPL expression levels (2-Ct) by QRT-PCR after 5-Aza-dC 
treatment on Daudi cell line is depicted (error bars indicate range factor 
difference). The histogram represents mean of three replicates. (** = P < 0.01 
by unpaired two-tailed Student's t-test). DNA methylation status of R1-LPL 
region in untreated and treated cells by 5 days is shown. Black and white circles 
represent methylated and unmethylated cytosine respectively and each row 
represents one bacterial clone. (C) Autologous T-cell activation on CLL B-cells. 
Black bars depict LPL expression at mRNA levels in control cultures (Ctrol) and 
in stimulated T-cell cultures (Act). Quantification was performed by QRT-PCR 
(2-Ct). Expression levels of control samples were normalized to 1 as 
expression relative unit. White bars represent the percentage of methylated 
CpG dinucleotides in control and activated T-cell cultures. (D) Representative 
CLL sample after stimulation with different microenvironment signals. LPL 
Methylation status: DNA methylation profile of R1-LPL region before and after 
different activation signals. Each row represents one bacterial clone in which 
black and white circles represent methylated and unmethylated CpG 
dinucleotides, respectively. LPL mRNA expression: LPL expression by RT-PCR 
is depicted in agarose gel stained with ethidium bromide. Um/LPL(pos) CLL 
sample was used as positive control and GAPDH was used as endogenous 
control. LPL protein expression: Protein expression was visualized by 
epifluorescence microscopy, Green: antibody anti-LPL, Blue dye: DAPI. 
Successful activations with autologous T-cells, CD40L/IL-4 and anti-BCR were 
corroborated by cytometry flow analysis with anti-CD19-PerCP, anti-CD25-PE, 
anti-CD80-PE and anti-CD86-FITC. 
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